Insomnia Chronic, Narcolepsy, REM Sleep Behavior Disorder
Conditions
Brief summary
Carry out precise and effective neuromodulation interventions, and develop new neuromodulation technologies for sleep disorders. Use phototherapy, transcranial electrical/magnetic stimulation and other therapies to conduct self-controlled intervention studies on insomnia, narcolepsy, and rapid eye movement sleep behavior disorder .
Interventions
DEVICETranscranial Magnetic Stimulation
repetitive transcranial magnetic stimulation, or transcranial direct current stimulation, or daytime timed bright light exposure
Sponsors
Second Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
\- Patients with insomnia, narcolepsy,and RBD that have been clearly diagnosed by specialists should sign the informed consent form.
Exclusion criteria
1. Patients with major neurological diseases such as multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumors, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, or those who have sustained neurological dysfunction or known structural brain abnormalities after significant head trauma are excluded. 2. A history of major depressive disorder or bipolar disorder within the past year, as defined in DSM-IV criteria. A history of schizophrenia (meeting DSM-IV criteria). 3. History of severe drug or alcohol abuse within the past year; 4. Any significant systemic illness or unstable medical condition that may make it difficult to comply with the protocol, such as severe autoimmune diseases or a history of cancer. 5. Have significant hearing, visual, or cognitive impairments, or are unable to participate in interviews in a meaningful way.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective sleep indicators and clinical sleep-related scales | From enrollment to the end of treatment at 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Resting-state electroencephalogram, resting-state functional magnetic resonance imaging, blood biochemical indicators | From enrollment to the end of treatment at 4 weeks |
Countries
China
Contacts
Primary ContactChun-Feng Liu, PhD
Outcome results
None listed